BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 2021;40:4457-71. [PMID: 34554329 DOI: 10.1007/s10067-021-05911-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. Semin Thromb Hemost 2022. [DOI: 10.1055/s-0042-1758869] [Reference Citation Analysis]
2 Jeffrey I Weitz, Zoltán Szekanecz, Christina Charles-Schoeman, Ivana Vranic, Burak Sahin, Sara A Paciga, Zhenyu Wang, Craig Hyde, David A Martin. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open 2022;8:e002571. [PMID: 36323490 DOI: 10.1136/rmdopen-2022-002571] [Reference Citation Analysis]
3 Wallace DV. Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc 2022;43:474-93. [PMID: 36335413 DOI: 10.2500/aap.2022.43.220076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Omair MA, Alkhelb SA, Ezzat SE, Boudal AM, Bedaiwi MK, Almaghlouth I. Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open Access Rheumatol 2022;14:231-42. [PMID: 36276408 DOI: 10.2147/OARRR.S284757] [Reference Citation Analysis]
5 Fang YF, Liu JR, Chang SH, Kuo CF, See LC. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis. Int J Rheum Dis 2022. [PMID: 35923107 DOI: 10.1111/1756-185X.14414] [Reference Citation Analysis]
6 Ma L, Willey J. The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. Thrombosis Update 2022;8:100117. [DOI: 10.1016/j.tru.2022.100117] [Reference Citation Analysis]
7 Jubber A, Woodward J, Hasan T, Moorthy A. Venous thromboembolism risk with Janus kinase inhibitors. Is it a class wide effect? Expert Opin Drug Saf 2022. [PMID: 35818715 DOI: 10.1080/14740338.2022.2100343] [Reference Citation Analysis]
8 Wang L, Xu Y, Jiang W, Liu J, Cao C, Shen Y, Xiao X, Ye Y. Is there association of olanzapine and pulmonary embolism: A case report. Clin Case Rep 2022;10:e05805. [PMID: 35662782 DOI: 10.1002/ccr3.5805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. J Clin Med 2022;11:2704. [PMID: 35628831 DOI: 10.3390/jcm11102704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang H, Zhu Z, Wang X, Wang X, Fan L, Wu R, Sun C. Application Effect of the Standard Operating Procedure in the Prevention of Venous Thromboembolism. J Healthc Eng 2022;2022:5019898. [PMID: 35035842 DOI: 10.1155/2022/5019898] [Reference Citation Analysis]
11 El-shabrawi Y, Rath T, Heiligenhaus A. Januskinase-Inhibitoren: Next-Generation-Therapie der Uveitis. Klin Monbl Augenheilkd. [DOI: 10.1055/a-1741-8104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nappi F, Iervolino A, Avtaar Singh SS. Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. Biomedicines 2022;10:437. [DOI: 10.3390/biomedicines10020437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ahmed S, Jacob B, Carsons SE, De Leon J, Reiss AB. Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk. Pharmaceuticals (Basel) 2021;15:11. [PMID: 35056068 DOI: 10.3390/ph15010011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Multiple drugs. Reactions Weekly 2021;1885:373-373. [DOI: 10.1007/s40278-021-07132-9] [Reference Citation Analysis]